Popular Trials
Brachytherapy
MRI-Guided HDR Brachytherapy for Prostate Cancer
This trial is testing a new, MRI-guided, high-dose-rate prostate brachytherapy procedure in two cohorts of patients with either locally recurrent or locally advanced prostate cancer. The trial will prospectively evaluate the technique in up to 100 patients to determine the technical limits and clinical feasibility of the new procedure.
Brachytherapy
HDR Brachytherapy for Prostate Cancer
This trial is studying HDR brachytherapy, a treatment that uses a small device to deliver strong radiation directly to prostate cancer cells. It targets patients with low and intermediate risk prostate cancer. The goal is to see if this method is effective and safe for these patients. High-dose-rate (HDR) brachytherapy is an advanced treatment for prostate cancer that allows precise delivery of high-dose radiation directly to the tumor, minimizing damage to surrounding tissues.
Popular Filters
Trials for Adenocarcinoma Patients
Procedure
Surgery vs Radiotherapy for Prostate Cancer
This trial is studying different treatment options for prostate cancer. It involves patients with low, intermediate, and high risk prostate cancer. The patients are divided into different groups based on their suitability for surgery as a
Brachytherapy
HDR Brachytherapy for Prostate Cancer
This trial is testing a treatment where small radioactive seeds are temporarily placed inside the prostate to kill cancer cells. It targets patients whose prostate cancer has come back but hasn't spread. The goal is to see if this focused treatment can reduce side effects compared to treating the whole prostate.
Radiation Therapy
Intense Radiotherapy for Prostate Cancer
This trial is designed to determine whether high risk prostate cancer patients can be safely treated with a shorter, more intense radiation therapy regimen. 3D-Conformal Radiotherapy (3D-CRT) or Intensity Modulated Radiotherapy (IMRT) will be used to deliver the required radiation dose. Patients will also receive 28 months of androgen deprivation therapy (LHRH agonist). The primary outcome of the study is the acute and delayed toxicity and the secondary outcomes include biochemical failure, prostate specific mortality rate, bone metastases free survival, the prognostic and predictive value of several biological variables. It is planned to recruit 250
Trials for Breast Cancer Patients
Angiogenesis Inhibitor
Cediranib + Olaparib for Cancer
This trial is testing a combination of two drugs to treat patients with solid tumors. Cediranib maleate blocks enzymes needed for cell growth, and olaparib may make the tumor more sensitive to Cediranib maleate.
Enzyme Inhibitor
BAY 1895344 + Chemotherapy for Bladder Cancer
This trial tests a new drug, BAY 1895344, combined with chemotherapy to treat advanced cancers. It aims to find the best dose and check for side effects. The treatment works by blocking enzymes needed for tumor growth and killing cancer cells. The trial focuses on patients with advanced solid tumors or urothelial cancer.
PARP Inhibitor
AZD5305 for Advanced Cancers
This trial is testing a new drug called AZD5305, which blocks a protein that helps cancer cells repair their DNA. It aims to see if the drug is safe and effective for patients with advanced solid tumors. By stopping the repair process, the drug hopes to kill cancer cells. AZD5305 has shown better tolerance in patients compared to earlier similar drugs.
Trials for Metastatic Patients
Corticosteroid
Apalutamide + Abiraterone Acetate + Prednisone for Prostate Cancer
This trial tests apalutamide added to a standard treatment for advanced prostate cancer. It targets patients whose cancer has spread and who haven't had chemotherapy. The treatment works by blocking and lowering male hormones that help cancer grow. Apalutamide has shown efficacy in treating different stages of prostate cancer.
Phase 3 Trials
Procedure
Surgery vs Radiotherapy for Prostate Cancer
This trial is studying different treatment options for prostate cancer. It involves patients with low, intermediate, and high risk prostate cancer. The patients are divided into different groups based on their suitability for surgery as a
Radiation Therapy
Intense Radiotherapy for Prostate Cancer
This trial is designed to determine whether high risk prostate cancer patients can be safely treated with a shorter, more intense radiation therapy regimen. 3D-Conformal Radiotherapy (3D-CRT) or Intensity Modulated Radiotherapy (IMRT) will be used to deliver the required radiation dose. Patients will also receive 28 months of androgen deprivation therapy (LHRH agonist). The primary outcome of the study is the acute and delayed toxicity and the secondary outcomes include biochemical failure, prostate specific mortality rate, bone metastases free survival, the prognostic and predictive value of several biological variables. It is planned to recruit 250
Trials With No Placebo
Procedure
Surgery vs Radiotherapy for Prostate Cancer
This trial is studying different treatment options for prostate cancer. It involves patients with low, intermediate, and high risk prostate cancer. The patients are divided into different groups based on their suitability for surgery as a
Brachytherapy
HDR Brachytherapy for Prostate Cancer
This trial is testing a treatment where small radioactive seeds are temporarily placed inside the prostate to kill cancer cells. It targets patients whose prostate cancer has come back but hasn't spread. The goal is to see if this focused treatment can reduce side effects compared to treating the whole prostate.
Radiation Therapy
Intense Radiotherapy for Prostate Cancer
This trial is designed to determine whether high risk prostate cancer patients can be safely treated with a shorter, more intense radiation therapy regimen. 3D-Conformal Radiotherapy (3D-CRT) or Intensity Modulated Radiotherapy (IMRT) will be used to deliver the required radiation dose. Patients will also receive 28 months of androgen deprivation therapy (LHRH agonist). The primary outcome of the study is the acute and delayed toxicity and the secondary outcomes include biochemical failure, prostate specific mortality rate, bone metastases free survival, the prognostic and predictive value of several biological variables. It is planned to recruit 250
View More Related Trials
Frequently Asked Questions
Introduction to canada prostate cancer
What are the top hospitals conducting canada prostate cancer research?
When it comes to advancing the treatment of prostate cancer, hospitals in Canada are making significant strides. The University Health Network in Toronto leads the way with seven active clinical trials focused on prostate cancer. While they may not have any completed trials specifically for this condition, their dedication and commitment to finding new solutions are unwavering. Similarly, the London Health Sciences Centre in London is actively engaged in seven ongoing clinical trials related to prostate cancer research. Like their counterparts in Toronto, they too have yet to complete any previous studies specifically targeting this disease.
Meanwhile, the Cross Cancer Institute in Edmonton and Odette Cancer Centre in Toronto both share a common goal of improving outcomes for patients with prostate cancer through six active clinical trials each; however, neither hospital has conducted any previous trials concerning this specific condition.
Interestingly enough, even outside Canadian borders shines Memorial Sloan Kettering Cancer Center—a renowned institution located in New york City. Though not based within Canada itself, it conducts an admirable number of six currently active clinical trials dedicated exclusively to prostate cancer research within Canada's healthcare landscape despite having no prior completed studies record
These hospitals represent a collective effort towards tackling one of the most prevalent cancers affecting men worldwide—prostate cancer. Through innovative clinical research initiatives and collaborations between medical professionals across multiple institutions and locations including those beyond national boundaries—they strive relentlessly to push boundaries and transform patient care by uncovering novel treatments that hold promise for better survival rates and improved quality of life for individuals battling this disease.
Which are the best cities for canada prostate cancer clinical trials?
When it comes to prostate cancer clinical trials in Canada, several cities stand out as top destinations for groundbreaking research. In Toronto, Ontario, there are currently 54 active trials focusing on treatments like Metformin, Darolutamide, and the Standard of care. Montreal, Quebec follows closely behind with 42 ongoing studies investigating treatments such as Metformin and Nivolumab alongside the Standard of care. Los Angeles, California is also a notable city with 32 active trials exploring treatment options like Radiation Therapy, Apalutamide, and Darolutamide+ADT. These cities offer individuals diagnosed with prostate cancer access to cutting-edge clinical trials that drive advancements in care and provide hope for improved outcomes.
Which are the top treatments for canada prostate cancer being explored in clinical trials?
Clinical trials are continuously pushing the boundaries in the search for effective treatments for prostate cancer. Currently, there are several promising options being explored:
- Daratumumab: This powerful drug is under investigation in multiple clinical trials.
- Belantamab mafodotin: Another potential treatment showing promise in ongoing research studies.
- Lenalidomide: A well-established medication that is also being evaluated as a possible option.
These treatments hold significant hope for advanced medical intervention against prostate cancer and may pave the way for improved outcomes and better quality of life for patients.
What are the most recent clinical trials for canada prostate cancer?
Canada is at the forefront of prostate cancer research, with several recent clinical trials offering groundbreaking possibilities for treatment. Among these trials, [18]F-PSMA-1007 PET/CT or PET/MRI has emerged as a promising diagnostic tool in phase 2. Another trial explores the efficacy of 18F-PSMA-1007 in treating prostate cancer in its advanced phase (phase 3). Additionally, a study investigates the combination of darolutamide and ADT as a potential therapy for Canadian patients with prostate cancer. Furthermore, researchers are evaluating the benefits of combining standard care with androgen deprivation therapy using Lupron Depot to enhance outcomes for individuals battling this disease. Lastly, a phase 2 trial examines stereotactic body radiotherapy (SABR) consolidation as an innovative approach towards improving treatment outcomes specifically for Canadian patients diagnosed with prostate cancer. These ongoing clinical trials hold immense promise and provide hope to those affected by this challenging condition.
What canada prostate cancer clinical trials were recently completed?
Recently completed clinical trials in Canada focused on advancing prostate cancer treatments. These groundbreaking studies have brought us closer to improving outcomes for patients battling this disease. Noteworthy among these trials is the completion of a trial investigating the effectiveness of a novel targeted therapy at University Hospital in Alberta. Additionally, McGill University conducted a successful trial exploring immunotherapy options for prostate cancer treatment. The results from these recent clinical trials provide valuable insights and hope for individuals with prostate cancer in Canada and beyond.